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Platelet-derived growth factor (PDGF)' was initially identified as a potent
mitogen in human serum for mesenchymally derived cells (1-3). PDGF is present
in platelet a granules and released from internal stores in association with platelet
activation at sites of injury (4, 5) . PDGF is a disulfide-linked heterodimeric
protein comprising A (non-sis) and B (sis) polypeptide chains (6-9). The B chain
of PDGF is structurally and functionally highly homologous to the protein
product of the v-sis oncogene, the transforming gene of simian sarcoma virus
(10, 11), and is encoded by the normal cellular homologue of v-sis, the c-sis
proto-oncogene (12, 13) . The c-sisand v-sis geneshave been cloned andexpressed
in Chinese hamster ovary (CHO) cells at high expression levels (Thomason, A.,
et al ., submitted for publication), permitting for the first time the direct appli-
cation of this growth factor into wounds in experimental animals to test a
functional role of PDGF in tissue repair .
Since PDGF and related proteins are released from platelets, monocytes, and
fibroblasts, andPDGF stimulatesboth chemotaxis andactivation of inflammatory
cells and fibroblasts in vitro (14-21), PDGF is thought to be an important
vulnerary agent for tissue repair processes in vivo . Another polypeptide growth
factor stored in the a granules of platelets, transforming growth factor type 0
(TGF-,B), is also considered important in tissue repair (22) . Both PDGF and TGF-
0 increase collagen formation, DNA content, and protein levels in wound
chambers implanted in rats (23, 24), and TGF-0 stimulates the reversible for-
mation of granulation tissue when injected subcutaneously into newborn mice
(25) . We have successfully demonstrated acceleration of wound healing in full-
thickness linear incision wounds made in rat skin (26) . A single application of
human TGF-(3 at the time of woundingadvanced by 2-3 d the breaking strength
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required to rupture the incision margins after 1 wk . The present studies dem-
onstrate marked augmentation of wound healing using human PDGF (hPDGF)
and recombinant c-sis homodimers (rPDGF-B), and reveal unique patterns of
response when compared with the results obtained with TGF-0 . Furthermore,
the recombinant c-sis homodimers on a molar basis are functionally as fully active
as PDGF in in vitro mitogenic and chemotactic assays .
Materials and Methods
Preparation of Growth Factors.
￿
Human PDGF was purified to homogeneity from
outdated platelets as described (6) . Recombinant human c-sis homodimers were produced
in Chinese hamster ovary cells after transfection with and amplification of the c-sis gene .
The protein was purified to apparent homogeneity from conditioned medium using a
procedure that included affinity chromatography over an anti-v-sis protein mAb column
(Thomason, A ., et al ., submitted for publication) . Purity was established by evaluating
iodinatedhPDGF andrPDGF-B in polyacrylamide gels by autoradiography . No endotoxin
was detectable in rPDGF-B preparations . Antisera raised against hPDGF (anti-PDGF 2 )
showed a high degree of crossreactivity with rPDGF-B using a solid-phase ELISA as
described (27), but was not crossreactive with other proteins in platelet extracts.
Mitogen Assay. Normal rat kidney cells (NRK, clone 49F ; American Type Culture
Collection, Rockville, MD) were grown to confluence in 10% FCS/Dulbecco's modified
essential medium (DMEM), trypsinized, and plated into 96-well microtiter plates (Falcon
Labware, Oxnard, CA) at a density of 2 x 109 cells/well in FCS-DMEM . Cells were
confluent within 3 d . Growth factors were assayed by addition of 200 Al [gH]thymidine
(120 nCi/well) in serum-free DMEM/Hams' F12 medium (1 :1, vol/vol), supplemented
with 35 mg/liter human transferrin, 5 mg/liter bovine insulin, 1 .2 Al/liter ethanolamine,
and 4.3 ug/liter sodium selenite . After 24 h, cells from triplicate wells were trypsinized
and harvested with an automated microharvester (Flow Laboratories, Inc ., McLean, VA),
fixed onto glass fiber filter paper with trichloroacetic acid, and counted . Human serum
(10%) from a normal individual was added as a positive control and background values
were subtracted from experimental values . In some experiments, 6 Ag anti-PDGF 2 IgG,
a rabbit polyclonal blocking antibody, was added per well just before addition of growth
factors.
Chemotaxis .
￿
Chemotaxis was determined in modified Boyden chambers, as previously
described (15, 28) . PBMCs and polymorphonuclear leukocytes (PMNs) were separated on
Ficoll-Hypaque gradients from peripheral blood obtained from healthy volunteers . Fetal
bovine ligament fibroblasts were obtained from explants of ligamentum nuchae as de-
scribed (29) . Growth factors were serially diluted in DMEM before use, and five high
power fields (fibroblasts) or grids (PMNs and monocytes) were counted from triplicate
samples .
Preparation of Growth Factors in Collagen.
￿
A bovine collagen suspension (Zyderm II ;
Collagen Corp ., Palo Alto, CA) with or without the addition of specific concentrations of
growth factors was applied using a tuberculin syringe containing 1 mg collagen per
incision . Preliminary experiments in vitro using '25I-PDGF suspended in collagen showed
about half the radioactivity was released into surrounding medium during the first hour,
and the remaining 50% was released from the collagen suspension during the next 23 h .
Despite the apparent delayed release of '21I-PDGF from collagen suspensions in vitro, it
remains possible that very different kinetics of release occur in vivo . However, preliminary
experiments in vivo revealed that rPDGF-B applied to wounds in a saline vehicle was not
active in augmenting healing . No significant differences in wound breaking strength were
found between collagen-treated wounds and saline-treated wounds in the present studies
(26).
Linear Incision Model .
￿
300-350-gm young adult male Sprague-Dawley rats (Sasco,
Inc ., Omaha, NB) had paired 6-cm full-thickness linear incisions placed through the skin
1 .5 cm on either side of the midline as described (26) . Wounds were coapted with three
surgical clips and the collagen-growth factor mixture was applied to one wound and9'76
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Mitogenic activity of
hPDGFand rPDGF-B. Confluent
NRK fibroblasts were incubated
with growth factors for 24 h at
specified dilutions in thepresence
of [9H]thymidine. For antibody
blocking experiments, 6 Ag anti-
PDGF2 was added to each well
just before theaddition ofgrowth
factor (0, hPDGF; O, rPDGF-B;
N, antibody + hPDGF; 9, anti-
body +rPDGF-B).
Collagen alone to the contralateral wound. Thus, each animal served as its own control.
The maximum load (breaking strength) tolerated by wounds harvested at various days
after wounding was measured with a tensometer (Tensometer 10; Monsanto Co., St.
Louis, MO) using two or three 8-mm wide skin strips from each wound as described (26).
Measurements were not performed on wounds showing evidence of infection, excessive
hemorrhage, or poor coaptation (<5% of all wounds).
Data Analysis. Eight rats were usually used for each variable to be tested in an
experiment. The control and treated wounds from each rat each had two to three matched
strips, 8 mm wide, perpendicular to the incision removed for tensometer analysis, and
one to two matched, paired samples taken for histologic analysis. Analysis ofvariance and
paired t-tests of breaking strength scores and differences between matched experimental
and control values were performed using the SAS data analysis system (Division of
Biostatistics, Washington University, St. Louis, MO). Breaking strength measurements
were performed blindly on coded samples.
Histology.
￿
Matched paired samples of experimental and control wounds from each rat
were placed immediately after harvest into acetic acid/ethanol (1 :99, vol/vol) fixative and
processed 24-48 h later. Paraffin-embedded paired growth factor-treated and control
thin sections were stained with hematoxylin, counterstained with eosin, and analyzed by
two independent observers in a blinded fashion by lightmicroscopy. Wounds were scored
on a scale from 0 to 4 for cellularity and the formation of granulation tissue as a function
of time after wounding. Reticulin and trichrome staining were performed by routine
methods.
Results
Mitogenic and Chemotactic Properties of rPDGF-B.
￿
In vitro functional activities
of rPDGF-B were determined and compared with hPDGF. rPDGF-B was first
shown to stimulate mitogenesis in NRK fibroblasts at picomolar levels; its activity
on a mole/mole basis was fully equal to hPDGF (Fig. 1). Anti-PDGF2, when
added tocellsjustbefore growth factors, abrogated the response (Fig. 1). rPDGF-
B was shown to be immunologically equivalent to hPDGF using this polyclonal
anti-PDGF antiserum (data not shown), and thus the mitogenic response of
rPDGF-B is highly specific and potent.
Asasecond testofthe biological functionality ofrPDGF-B, chemotacticactivity
was assayed in modified Boyden chambers. Peak chemotaxis for fibroblasts was
observed at 30 ng/ml, while peak activity for monocytes was obtained at 10
ng/ml (Fig. 2A). These values are essentially identical to those reported previ-U =
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Chemotactic activity of rPDGF-B.
Dilutions of growth factors were tested in mod-
ified Boyden chambers as described in the Ma-
terials and Methods. (A) Bovine ligamentum
nuchae fibroblasts and humanperipheral blood
monocytes. (B) Humanpolymorphonuclear leu-
kocytes tested in the absence or presence of
anti-PDGF2 (a'P2), which was mixed with
rPDGF-B and then serially diluted. Anti-
PDGF2 waspresent at 140wg/ml when rPDGF-
B was 30 ng/ml. Anti-PDGF2 had no effect on
thechemotactic activity of FMLP.
ously for hPDGF (fibroblasts 30 ng/ml, monocytes 20 ng/ml) (14, 15). Polymor-
phonuclear leukocytes were maximally active at 3 ng/ml rPDGF-B (Fig. 2B).
Previous experiments with hPDGF showed maximal reactivity of PMNs at 1-5
ng/ml (14) . The magnitude of the chemotactic responses was comparable to the
response obtained using optimal concentrations of the FMLP peptide. The
apparent inhibition of the chemotactic response at higher concentrations of
rPDGF-B reflects cell aggregation, which occurs when concentrations of agonist
exceed the optimum concentration for chemotaxis, and was observed previously
with hPDGF (14, 15) . Addition of anti-PDGF2 to samples before assay sharply
reduced the chemotactic response of PMNs to 3 ng/ml rPDGF-B by 80% (Fig.
2B), without affecting the chemotactic activity ofFMLP (datanot shown), thereby
establishing the specificity of chemotactic response to rPDGF-B, and not to
undetectable levels of contaminating proteins.
In Vivo Activities of rPDGF-B.
￿
Since rPDGF-B appeared identical to hPDGF
in stimulating inflammatory cells in vitro, a previously developed rat linear skin
incision model (26) was used to test the potential of rPDGF-B to augment wound
healing in vivo. When tested at 20 gg per incision, both rPDGF-B and hPDGF
induced significant increases in the breaking strength of incisional wounds at day
7 (Table 1). Further experiments were undertaken with rPDGF-B to determine
optimal doses (Fig. 3A). Small but significant increases in breaking strength after
5 d were observed when 2,ug rPDGF-B were applied per incision on the day of
wounding. Statistically significant increases in breaking strength to 143% and
170% of control wounds were observed at 5 and 20 ug rPDGF-B per incision,
respectively.978
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TABLE I
Comparison ofBreaking Strengths ofDay 7 Incisional Wounds Treatedwith 20 Ag ofEither
hPDGF or rPDGF-B at the Time of Wounding
* Mean f SEM.
$ n, number of strips tested, two to three matched strips obtained from each growth factor treated
and control wound.
sCompared with matched, paired control wounds usinga two-tailed, paired t-test.
TABLE II
Histological Evaluation of rPDGF-B-treated and Untreated Wounds
* Three to six paired incisional wounds were analyzed per time point. Individual days analyzed
include 0.5, 1, 2, 3, 4, 5, 7, 10, 14, and 21 .
$ Paraffin-embedded paired growth factor-treated and control wound thin sections were stained
with hematoxylin and eosin and each parameter was graded on a scale from 0-4 as a function of
days after wounding by two blinded individuals. Average scores are presented. rP, rPDGF-B
treated; C, paired control wounds.
To determine whether rPDGF-Bcontinued to enhance woundhealingbeyond
the initial week after wounding, the time course of the rPDGF-B-induced
augmentation of breaking strength was tested. Increases in breaking strength of
rPDGF-B-treated wounds beginning at day 3 and extending through day 21
after wounding were observed (Fig. 3B). Although statistically significant differ-
ences between growth factor-treated andcontrol wounds were observed through
day 7 after wounding, even more striking differences were observed at days 10,
14, and 21 after wounding when the breaking strength of rPDGF-B-treated
wounds diverged markedly from controls, with a maximum difference in break-
ing strength of 824 g between treated and control wounds at day 21 (Fig. 3B).
Analysis of Directed Cellular Migration.
￿
Semiquantitative histologic examina-
tion of treated and control wounds revealed time-dependent changes in cellular
composition which correlated well with the observed differences in breaking
strength (Table II). Sections obtained from both hPDGF- and rPDGF-B-treated
wounds within 2 d of wounding showed an increased influx of inflammatory
cells, primarily neutrophils and monocytes, into growth factor-treated wounds
when compared with control wounds. Multiple sections were used to confirm
these results. Increased fibroblast migration into hPDGF- and rPDGF-B-treated
wounds was demonstrated at this point, although the fibroblast migration into
Days after
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FIGURE 3. . Breaking strength oflinear incision wounds treated with rPDGF-B . Growth factor
was applied in a collagen vehicle at the time of wounding . Matched paired experimental and
control wounds were harvested at specified days, coded, and tested blindly on the tensometer
for the maximum load (breaking strength) tolerated before breaking . The breaking strength
scores (mean t SEM) for 16-20 strips from eight rats (one experimental and one matched
control incisional wound per rat) are represented by each data point .pvalues were calculated
from a paired t test. (A) Effect of rPDGF-B on 5-d wounds, as a function o£ dose, compared
with paired collagen control wounds . (B) effect of 20 wg rPDGF-B per incision as a function
of time after wounding . rPDGF-B was applied on the day of surgery then wounds were
harvested at the times shown and breaking strength was compared with matched control
wounds containing only the collagen vehicle . Note the break on they axis. The differences in
breaking strength between paired experimental and control wounds are depicted in the
histograms for each day(mean ± SEM) . p values are in parentheses.980
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FIGURE 4.
￿
Histological evaluation of paired wounds treated with rPDGF-B or the collagen
vehicle alone . Allwounds were full thicknessandextended through the panniculus carnosus .
Sections adjacent to matched strips used for tensometry were processed, embedded, sectioned,
and stained with hetnatoxylin and eosin (H and E), reticulin, or trichrome using routine
methods . (A-D) day 4 wounds . (A) rPDGF-B, 10 wg, H and E, x57; (B) matched collagen
control, H and E, X57; (C) rPDGF-B, 10 Wg, reticulin, x100 ; (D) matched collagen control,
reticulin, X100 . (E-H) day 14 wounds . (E) rPDGF-B, 20 Wg, H and E, X100 ; (F) matched
collagen control, H and E, X100 ; (G)rPDGF-B, 20 beg, trichrome, X57; (H) matched collagen
control, trichrome, X57. Arrows demarcate the wound boundaries . See text for descriptions .
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wounds was substantially greater with time. By day 4 after wounding, rPDGF-
B-treatedwounds were markedly infiltrated with fibroblasts andnewgranulation
tissue when compared with control sections (Table 11, Fig. 4, A and B). Sections
from multiple rPDGF-B wounds at each time point were analyzed through day
21 . Growth factor-treated wounds consistently showed large differences in
granulation tissue relative to controls, associated with the observed differences
in breaking strength.
Whereas the in vivo sequence of directed cellular migration correlated well
with that predicted by the sensitivity of the cells to the chemotactic signal in vitro
(Fig. 2), and correlated well with increased wound breaking strength (Fig. 3),
collagen deposition is the single best correlate with enhanced wound strength.
Evidence of increased new collagen synthesis in rPDGF-B-treated and matched
control wounds was therefore sought using the reticulin stain on day 4 wounds
(Fig. 4, c and d) and by trichrome staining of day 14 rPDGF-B-treated and
paired control wounds (Fig. 4, g and h). Both the increased reticulin fibers
observed at day 4 and the pale trichrome staining of the collagen relative to
adjacent dermal collagen at day 14 in rPDGF-B-treated wounds likely reflect
primarily newly synthesized collagen. The increased basophilic demarcation of
the scar in the growth factor-treated wounds was also observed on hematoxylin
and eosin-stained sections through day 14 (Fig. 4, e andf). Increased granulation
tissue was still present at the base of the rPDGF-B-treated wound (Fig. 4g) at
day 14, compared with the matched control (Fig. 4h, and Table II).
Discussion
in the present study, recombinant c-sis homodimers have been shown for the
first time to function identically to human PDGF immunologically and in stim-
ulating thefunctional activities of mitogenesisand chemotaxis in vitroat identical
concentrations. Because these and previous results have demonstrated not only
the positive chemotactic potential of PDGF but also its ability to activate inflam-
matory cells (14-18) and to stimulate the secretion of collagenase by fibroblasts
(30), we wished to demonstrate the in vivo activity of PDGF in tissue repair.
Using a rat linear incision model and a single application of growth factor
dissolvedin acollagen suspension at the time of wounding, we observed consistent
and significant stimulation of wound healing, beginning at 2 fcg rPDGF-B per
incision, and increasing in a dose-dependent fashion to 170% of control wounds
with 20 Ag rPDGF-B per incision. Stimulation by rPDGF-B was observed as early
as day 3, when collagen synthesis is initially observed in this model (31, 32), and
increased through day 7, producing a 2-d acceleration of healing in the first
week. A single application of purified hPDGF on the day of wounding also
augmented the breaking strength of incisional wounds harvested at day 7,
establishing in yet another parameter that the recombinant protein was fully as
active as PDGF itself. During the second and third weeks after wounding, a 4-
6-d acceleration of healing was observed in rPDGF-B-treated wounds compared
with control wounds treated with collagen alone. Examination of wounds at later
times after surgery will be necessary to determine if the rPDGF-B-induced
augmentation of healing persists, although preliminary results indicate increasingPIERCE ET AL.
￿
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differences in breaking strength are present through at least day 49 in rPDGF-
B-treated wounds (our unpublished results).
Since most of the rPDGF-B is released from the collagen vehicle during the
first 24 h in vitro (see Materials and Methods), we suspect that the growth factor
induced a cascade effect initiated by cells migrating into wounds in response to
the initial stimulus. As tissue macrophages and fibroblasts approach the wound
and thus are exposed to higher concentrations of rPDGF-B, these cells in turn
become activated, releasing additional growth factors and other chemotactically
active peptides (18, 19, 21). The observed differences in rPDGF-B-treated
wounds at later weeks after wounding thus appear to result from a multiplicity
of cellular events triggered and to some extent sustained by rPDGF-B. These
results are in contrast to findings using human TGF-a in the same experimental
model (26), in which a more marked stimulatory effect was observed in the first
week after wounding. However, differences between TGF-,#-treated and control
wounds remained constant or decreased during the second week. TGF-a stimu-
lates the synthesis of extracellular matrix proteins, such as procollagen type I
and fibronectin, directly (33-35), while hPDGF does not appear to directly
stimulate procollagen synthesis but does activate collagenase gene expression
(30), which is required for wound remodeling. Remodeling begins after the
initial deposition ofcollagen and is needed for the structural integrity ofthe scar
(36, 37). Thus TGF-/3 may directly stimulate collagen synthesis by wound
fibroblasts while hPDGF may be acting later in healing or indirectly to induce
the secretion ofother growth factors such as TGF-(3 (Masakowski, V. R., and G.
F. Pierce, unpublished observations) and additional PDGF-like polypeptides by
wound macrophages, endothelial cells, etc., which can then directly stimulate
collagen synthesis by fibroblasts (38). Thus rPDGF-B and human TGF-O appear
to augment wound healing by different mechanisms, as perhaps reflected in
differences in collagen degradation and synthesis. However, it cannot be ex-
cluded that in vivo, the two growth factors may be released from the collagen
vehicle at very different kinetic rates. Experiments to analyze these hypotheses
are in progress.
Woundsanalyzed histologically within the first week showeda marked increase
in neutrophils, monocytes, and fibroblasts in hPDGF- and rPDGF-B-treated
wounds and a large increase in granulation tissue by day 4 after wounding, in
comparison to matched, paired control incisions analyzed on the same days after
wounding. These results thus correlate well with earlier in vitro observations
and an in vivo study using wound chambers (14-18, 23). Importantly, although
the analysis is only semiquantitative, the observations that increased numbers of
inflammatory cells and fibroblasts migrate into incisional wounds during healing
correlates with the predicted migration of these cells based upon the optimal
doses required for chemotaxis in vitro. Taken together, these findings support a
highly important roleofPDGFasachemoattractant infacilitatingwound healing,
over and above its role in mitogenesis.
The findings ofsimilar resultsin vivo using hPDGF, an A-Bchain heterodimer,
and rPDGF-B, a B-B chain homodimer, are interesting with respect to the
proposed function of the A chain (non-sis) of PDGF (PDGF-A), which is 60%
homologous to the B chain (10). PDGF-A was recently shown to be synthesized984
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and released by fibroblasts in culture which had been activated by PDGF (20),
suggesting important extracellular autocrine and paracrine functions of PDGF-
A. The recent cDNA cloning of the A chain (39, 40) should permit direct analysis
of functional differences between A-A and B-B homodimeric proteins (41) and
the PDGF A-B heterodimer. Moreover, the availability of purified recombinant
human PDGF in much larger quantities than the quantities of PDGF that can be
readily isolated from platelets should permit evaluation of PDGF in the treatment
of impaired wound healing.
Summary
Human platelet-derived growth factor (hPDGF) is likely to be important in
stimulating tissue repair, based upon its in vivo chemotactic and stimulatory
activities for inflammatory cells and fibroblasts and upon the presence of PDGF
and related proteins in platelets, macrophages, and activated fibroblasts, cell
types that make up the milieu of the healing wound. Recombinant human c-sis
(rPDGF-B), homodimers of the B chain of PDGF, were compared with hPDGF
in vitro. rPDGF-B was immunologically similar to hPDGF and, at identical
concentrations, similar to hPDGF in stimulating fibroblast mitogenesis and
chemotaxis of polymorphonuclear leukocytes, monocytes, and fibroblasts. Puri-
fied hPDGF and rPDGF-B were also tested in vivo for potency in a model of
tissue repair using a linear incision wound through rat dermis. A single applica-
tion of hPDGF or rPDGF-B (2-20 Ag/wound) in a slow release vehicle at the
time of wounding resulted in a dose-dependent, statistically highly significant
increase of breaking strength of treated wounds. Wound healing in animals
treated with rPDGF-B was 170% stronger and accelerated by 2 d during the
first week over control wounds and by 4-6 d over the next 2 wk. Histologic
evaluation of growth factor-treated wounds correlated the in vitro chemotactic
activity and the accelerated healing of wounds with a striking inflammatory cell
infiltrate early after wounding, markedly increased formation of granulation
tissue by 4-d, and increased fibrosis by 14 d in comparison to control wounds.
The results thus demonstrate that rPDGF-B is fully active in in vitro tests of
mitogenesis and chemotaxis and, for the first time, demonstrate directly that
PDGF significantly advances wound healing in incisional wounds ofexperimental
animals.
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